Skip to main content

Table 3 Subject groups used

From: Diagnostic markers based on a computational model of lipoprotein metabolism

Subject group Number of subjects Ref. Included in 'normo-lipidemic' group Included in 'dys-lipidemic' group
Normolipidemic controls 3
(in: N1, N3, N5)
[19] x  
Normolipidemic controls 6 [20] x  
Normolipidemic controls: apoE 3/3 subjects. 5 [17] x  
Normolipidemic controls 9 [21] x  
All subjects 12 [22] x  
phenotype 'A' (large LDL particle size) 9 [18] x  
mixed dyslipidemia prior to treatment (Baseline) 5
(in: P2, P3, P5, P7, P8)
[24]   x
mixed dyslipidemia prior to treatment (Baseline) 11 [25]   x
kidney patients 9 [21]   x
hypothyroid subjects before and during T4 therapy 10
(excluded before T4: 6; during T4: 3)
[26]   x
HIV treatment-associated hyperlipidemic subjects 5 [23]   x
phenotype 'B' subjects, with small LDL particle size 4
(in: subjects 17-20)
[18]   x
LPL -/- 3 [16]   
apoE 2/2 4 [17]   
apoE 4/4 5 [17]   
homozygous familial hypercholesterolemia 3
(in: FH1, FH2, FH4)
[19]   
familial defective apoB 3 [29]   
S447X; a single nucleotide polymorphism in the LPL gene 5 [30]   
Total used for normolipidemic group 44    
Total used for dyslipidemic group 44    
  1. Subject groups used for normolipidemia, dyslipidemia, and genetic disorders. If subjects needed to be excluded from a group because of a lack of steady state in the data (in- and efflux balance), individual subjects are mentioned.